Cargando…
Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines
OBJECTIVES: The next round of the American Society for Colposcopy and Cervical Pathology (ASCCP)-sponsored cervical cancer screening and management guidelines will recommend clinical actions based on risk, rather than test-based algorithms. This article gives preliminary risk estimates for the scree...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625966/ https://www.ncbi.nlm.nih.gov/pubmed/28953116 http://dx.doi.org/10.1097/LGT.0000000000000343 |
_version_ | 1783268470477029376 |
---|---|
author | Demarco, Maria Lorey, Thomas S. Fetterman, Barbara Cheung, Li C. Guido, Richard S. Wentzensen, Nicolas Kinney, Walter K. Poitras, Nancy E. Befano, Brian Castle, Philip E. Schiffman, Mark |
author_facet | Demarco, Maria Lorey, Thomas S. Fetterman, Barbara Cheung, Li C. Guido, Richard S. Wentzensen, Nicolas Kinney, Walter K. Poitras, Nancy E. Befano, Brian Castle, Philip E. Schiffman, Mark |
author_sort | Demarco, Maria |
collection | PubMed |
description | OBJECTIVES: The next round of the American Society for Colposcopy and Cervical Pathology (ASCCP)-sponsored cervical cancer screening and management guidelines will recommend clinical actions based on risk, rather than test-based algorithms. This article gives preliminary risk estimates for the screening setting, showing combinations of the 2 most important predictors, human papillomavirus (HPV) status and cytology result. MATERIALS AND METHODS: Among 1,262,713 women aged 25 to 77 years co-tested with HC2 (Qiagen) and cytology at Kaiser Permanente Northern California, we estimated 0–5-year cumulative risk of cervical intraepithelial neoplasia (CIN) 2+, CIN 3+, and cancer for combinations of cytology (negative for intraepithelial lesion or malignancy [NILM], atypical squamous cells of undetermined significance [ASC-US], low-grade squamous intraepithelial lesion [LSIL], atypical squamous cells cannot exclude HSIL [ASC-H], high-grade squamous intraepithelial lesion [HSIL], atypical glandular cells [AGC]) and HPV status. RESULTS: Ninety percent of screened women had HPV-negative NILM and an extremely low risk of subsequent cancer. Five-year risks of CIN 3+ were lower after HPV negativity (0.12%) than after NILM (0.25%). Among HPV-negative women, 5-year risks for CIN 3+ were 0.10% for NILM, 0.44% for ASC-US, 1.8% for LSIL, 3.0% for ASC-H, 1.2% for AGC, and 29% for HSIL+ cytology (which was very rare). Among HPV-positive women, 5-year risks were 4.0% for NILM, 6.8% for ASC-US, 6.1% for LSIL, 28% for ASC-H, 30% for AGC, and 50% for HSIL+ cytology. CONCLUSIONS: As a foundation for the next guidelines revision, we confirmed with additional precision the risk estimates previously reported for combinations of HPV and cytology. Future analyses will estimate risks for women being followed in colposcopy clinic and posttreatment and will consider the role of risk modifiers such as age, HPV vaccine status, HPV type, and screening and treatment history. |
format | Online Article Text |
id | pubmed-5625966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-56259662017-10-17 Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines Demarco, Maria Lorey, Thomas S. Fetterman, Barbara Cheung, Li C. Guido, Richard S. Wentzensen, Nicolas Kinney, Walter K. Poitras, Nancy E. Befano, Brian Castle, Philip E. Schiffman, Mark J Low Genit Tract Dis Original Research Articles: Cervix and HPV OBJECTIVES: The next round of the American Society for Colposcopy and Cervical Pathology (ASCCP)-sponsored cervical cancer screening and management guidelines will recommend clinical actions based on risk, rather than test-based algorithms. This article gives preliminary risk estimates for the screening setting, showing combinations of the 2 most important predictors, human papillomavirus (HPV) status and cytology result. MATERIALS AND METHODS: Among 1,262,713 women aged 25 to 77 years co-tested with HC2 (Qiagen) and cytology at Kaiser Permanente Northern California, we estimated 0–5-year cumulative risk of cervical intraepithelial neoplasia (CIN) 2+, CIN 3+, and cancer for combinations of cytology (negative for intraepithelial lesion or malignancy [NILM], atypical squamous cells of undetermined significance [ASC-US], low-grade squamous intraepithelial lesion [LSIL], atypical squamous cells cannot exclude HSIL [ASC-H], high-grade squamous intraepithelial lesion [HSIL], atypical glandular cells [AGC]) and HPV status. RESULTS: Ninety percent of screened women had HPV-negative NILM and an extremely low risk of subsequent cancer. Five-year risks of CIN 3+ were lower after HPV negativity (0.12%) than after NILM (0.25%). Among HPV-negative women, 5-year risks for CIN 3+ were 0.10% for NILM, 0.44% for ASC-US, 1.8% for LSIL, 3.0% for ASC-H, 1.2% for AGC, and 29% for HSIL+ cytology (which was very rare). Among HPV-positive women, 5-year risks were 4.0% for NILM, 6.8% for ASC-US, 6.1% for LSIL, 28% for ASC-H, 30% for AGC, and 50% for HSIL+ cytology. CONCLUSIONS: As a foundation for the next guidelines revision, we confirmed with additional precision the risk estimates previously reported for combinations of HPV and cytology. Future analyses will estimate risks for women being followed in colposcopy clinic and posttreatment and will consider the role of risk modifiers such as age, HPV vaccine status, HPV type, and screening and treatment history. Lippincott Williams & Wilkins 2017-10 2017-09-26 /pmc/articles/PMC5625966/ /pubmed/28953116 http://dx.doi.org/10.1097/LGT.0000000000000343 Text en Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society for Colposcopy and Cervical Pathology. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Original Research Articles: Cervix and HPV Demarco, Maria Lorey, Thomas S. Fetterman, Barbara Cheung, Li C. Guido, Richard S. Wentzensen, Nicolas Kinney, Walter K. Poitras, Nancy E. Befano, Brian Castle, Philip E. Schiffman, Mark Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines |
title | Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines |
title_full | Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines |
title_fullStr | Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines |
title_full_unstemmed | Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines |
title_short | Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines |
title_sort | risks of cin 2+, cin 3+, and cancer by cytology and human papillomavirus status: the foundation of risk-based cervical screening guidelines |
topic | Original Research Articles: Cervix and HPV |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625966/ https://www.ncbi.nlm.nih.gov/pubmed/28953116 http://dx.doi.org/10.1097/LGT.0000000000000343 |
work_keys_str_mv | AT demarcomaria risksofcin2cin3andcancerbycytologyandhumanpapillomavirusstatusthefoundationofriskbasedcervicalscreeningguidelines AT loreythomass risksofcin2cin3andcancerbycytologyandhumanpapillomavirusstatusthefoundationofriskbasedcervicalscreeningguidelines AT fettermanbarbara risksofcin2cin3andcancerbycytologyandhumanpapillomavirusstatusthefoundationofriskbasedcervicalscreeningguidelines AT cheunglic risksofcin2cin3andcancerbycytologyandhumanpapillomavirusstatusthefoundationofriskbasedcervicalscreeningguidelines AT guidorichards risksofcin2cin3andcancerbycytologyandhumanpapillomavirusstatusthefoundationofriskbasedcervicalscreeningguidelines AT wentzensennicolas risksofcin2cin3andcancerbycytologyandhumanpapillomavirusstatusthefoundationofriskbasedcervicalscreeningguidelines AT kinneywalterk risksofcin2cin3andcancerbycytologyandhumanpapillomavirusstatusthefoundationofriskbasedcervicalscreeningguidelines AT poitrasnancye risksofcin2cin3andcancerbycytologyandhumanpapillomavirusstatusthefoundationofriskbasedcervicalscreeningguidelines AT befanobrian risksofcin2cin3andcancerbycytologyandhumanpapillomavirusstatusthefoundationofriskbasedcervicalscreeningguidelines AT castlephilipe risksofcin2cin3andcancerbycytologyandhumanpapillomavirusstatusthefoundationofriskbasedcervicalscreeningguidelines AT schiffmanmark risksofcin2cin3andcancerbycytologyandhumanpapillomavirusstatusthefoundationofriskbasedcervicalscreeningguidelines |